open access

Vol 80, No 1 (2009)
ARTICLES
Get Citation

Serum visfatin concentration is elevated in pregnant women irrespectively of the presence of gestational diabetes

Maria Górska, Adam Krętowski, Agnieszka Nikołajuk, Anna Zonenberg, Beata Telejko, Mariusz Kuźmicki, Jacek Szamatowicz
Ginekol Pol 2009;80(1).

open access

Vol 80, No 1 (2009)
ARTICLES

Abstract

Summary Objectives: The aim of the present study was to compare serum concentrations of a recently identified namely – visfatin between pregnant women with normal glucose tolerance (NGT) and gestational diabetes mellitus (GDM), as well as non-pregnant healthy subjects. Materials and methods: Serum visfatin concentration was measured in 61 patients with GDM, 63 pregnant subjects with NGT and 36 non-pregnant healthy women by means of an immunoassay. Results: Median visfatin levels did not differ in the women with GDM (14.8 [10.8-17.3] μg/l) and NGT (15.3 [11.8-19.4] μg/l), but were significantly higher than those found in the non-pregnant women (11.4 [8.6-15.2] μg/l, p=0.0008 vs NGT and p=0.008 vs GDM group). Visfatin concentrations correlated significantly with fasting insulin (R=0.20, p=0.01), HOMA-IR (R=0.19, p=0.02) and HOMA-%B (R=0.23, p=0.004). Stepwise regression analysis revealed that serum visfatin levels were significantly predicted only by HbA1c values (b=0.21, p=0.04). Conclusions: Serum visfatin concentrations are elevated in pregnant women, irrespectively of their glucose tolerance status. This elevation may be caused by an additional secretion of visfatin from the placenta, however other possible sources of visfatin should also be taken into account.

Abstract

Summary Objectives: The aim of the present study was to compare serum concentrations of a recently identified namely – visfatin between pregnant women with normal glucose tolerance (NGT) and gestational diabetes mellitus (GDM), as well as non-pregnant healthy subjects. Materials and methods: Serum visfatin concentration was measured in 61 patients with GDM, 63 pregnant subjects with NGT and 36 non-pregnant healthy women by means of an immunoassay. Results: Median visfatin levels did not differ in the women with GDM (14.8 [10.8-17.3] μg/l) and NGT (15.3 [11.8-19.4] μg/l), but were significantly higher than those found in the non-pregnant women (11.4 [8.6-15.2] μg/l, p=0.0008 vs NGT and p=0.008 vs GDM group). Visfatin concentrations correlated significantly with fasting insulin (R=0.20, p=0.01), HOMA-IR (R=0.19, p=0.02) and HOMA-%B (R=0.23, p=0.004). Stepwise regression analysis revealed that serum visfatin levels were significantly predicted only by HbA1c values (b=0.21, p=0.04). Conclusions: Serum visfatin concentrations are elevated in pregnant women, irrespectively of their glucose tolerance status. This elevation may be caused by an additional secretion of visfatin from the placenta, however other possible sources of visfatin should also be taken into account.
Get Citation

Keywords

visfatin, pregnancy, Gestational diabetes mellitus

About this article
Title

Serum visfatin concentration is elevated in pregnant women irrespectively of the presence of gestational diabetes

Journal

Ginekologia Polska

Issue

Vol 80, No 1 (2009)

Bibliographic record

Ginekol Pol 2009;80(1).

Keywords

visfatin
pregnancy
Gestational diabetes mellitus

Authors

Maria Górska
Adam Krętowski
Agnieszka Nikołajuk
Anna Zonenberg
Beata Telejko
Mariusz Kuźmicki
Jacek Szamatowicz

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl